Genes & biomarkers
PIK3CA variants
PIK3CA · PI3K pathway
Relevant to treatment selection in some hormone receptor-positive breast cancers.
Sources checked · Introductory guide
On this page
What does this result mean?
PIK3CA is part of the PI3K growth pathway. Some variants make signaling overactive. The gene name alone does not establish hormone receptor or HER2 status.[1]
How does it connect to treatment?
Alpelisib with fulvestrant is an option for selected PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after endocrine therapy. This does not establish the same treatment for every PIK3CA-altered cancer.[2]
What should I check in my report?
Review variant classification, ER/PR/HER2 and previous endocrine therapy. If a drug is considered, ask about baseline checks and monitoring, including blood glucose.
Questions for your care team
- Do my receptor status and treatment history meet criteria for PI3K-targeted treatment?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.